Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. / Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón.
Gastroenterol Hepatol
; 42(8): 502-511, 2019 Oct.
Article
em En, Es
| MEDLINE
| ID: mdl-31472990
ABSTRACT
Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Carcinoma Hepatocelular
/
Hepatite C Crônica
/
Neoplasias Hepáticas
/
Recidiva Local de Neoplasia
Idioma:
En
/
Es
Ano de publicação:
2019
Tipo de documento:
Article